BidaskClub lowered shares of Cerus (NASDAQ:CERS) from a hold rating to a sell rating in a research report released on Thursday.
A number of other equities research analysts also recently issued reports on CERS. Cantor Fitzgerald reiterated a reduce rating and set a $9.00 price target on shares of Cerus in a research report on Friday, July 20th. Zacks Investment Research upgraded shares of Cerus from a hold rating to a buy rating and set a $8.50 price target for the company in a research report on Tuesday, July 24th. Finally, Cowen set a $10.00 price target on shares of Cerus and gave the company a buy rating in a research report on Friday, August 3rd. One research analyst has rated the stock with a sell rating, two have given a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has a consensus rating of Buy and an average price target of $8.00.
Shares of CERS opened at $6.49 on Thursday. Cerus has a twelve month low of $2.75 and a twelve month high of $8.05. The company has a market capitalization of $964.80 million, a price-to-earnings ratio of -11.59 and a beta of 1.51. The company has a debt-to-equity ratio of 0.29, a quick ratio of 4.57 and a current ratio of 5.03.
Cerus (NASDAQ:CERS) last posted its quarterly earnings results on Thursday, August 2nd. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.11) by $0.01. Cerus had a negative net margin of 76.37% and a negative return on equity of 82.60%. The company had revenue of $15.42 million during the quarter, compared to the consensus estimate of $13.58 million. During the same period last year, the firm earned ($0.16) EPS. The company’s revenue for the quarter was up 61.8% on a year-over-year basis. Analysts expect that Cerus will post -0.43 EPS for the current year.
In other news, insider Richard J. Benjamin sold 35,416 shares of Cerus stock in a transaction that occurred on Tuesday, August 14th. The shares were sold at an average price of $7.20, for a total transaction of $254,995.20. Following the completion of the sale, the insider now directly owns 35,416 shares in the company, valued at approximately $254,995.20. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Kevin Dennis Green sold 50,000 shares of Cerus stock in a transaction that occurred on Tuesday, August 28th. The shares were sold at an average price of $7.50, for a total transaction of $375,000.00. Following the sale, the chief financial officer now owns 110,825 shares of the company’s stock, valued at $831,187.50. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 90,982 shares of company stock valued at $669,514. Insiders own 6.80% of the company’s stock.
Hedge funds have recently bought and sold shares of the company. Rhumbline Advisers raised its position in shares of Cerus by 10.9% during the 1st quarter. Rhumbline Advisers now owns 107,397 shares of the biotechnology company’s stock worth $589,000 after purchasing an additional 10,580 shares during the last quarter. Swiss National Bank raised its position in shares of Cerus by 20.3% during the 1st quarter. Swiss National Bank now owns 221,900 shares of the biotechnology company’s stock worth $1,216,000 after purchasing an additional 37,500 shares during the last quarter. Schwab Charles Investment Management Inc. raised its position in shares of Cerus by 27.6% during the 1st quarter. Schwab Charles Investment Management Inc. now owns 627,912 shares of the biotechnology company’s stock worth $3,441,000 after purchasing an additional 136,003 shares during the last quarter. Northern Trust Corp raised its position in shares of Cerus by 10.4% during the 1st quarter. Northern Trust Corp now owns 1,462,663 shares of the biotechnology company’s stock worth $8,015,000 after purchasing an additional 138,190 shares during the last quarter. Finally, BlackRock Inc. raised its position in shares of Cerus by 11.9% during the 1st quarter. BlackRock Inc. now owns 9,496,161 shares of the biotechnology company’s stock worth $52,040,000 after purchasing an additional 1,010,450 shares during the last quarter. Institutional investors own 59.76% of the company’s stock.
Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System is based on its proprietary technology for controlling biological replication; and targets and inactivates blood-borne pathogens, such as viruses, bacteria, and parasites, as well as harmful white blood cells, while preserving the therapeutic properties of platelet, plasma, and red blood cell transfusion products.
Further Reading: Using the New Google Finance Tool
Receive News & Ratings for Cerus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus and related companies with MarketBeat.com's FREE daily email newsletter.